Welcome to our dedicated page for Park Ha Biological Technology Co., Ltd. SEC filings (Ticker: BYAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Park Ha Biological Technology Co., Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Park Ha Biological Technology Co., Ltd.'s regulatory disclosures and financial reporting.
Park Ha Biological Technology Co., Ltd. reported net revenue of $1,257,689 for the six months ended April 30, 2026, up 1% from $1,239,197, with overall gross margin at 96%. Revenue mix shifted toward product sales to non‑franchise customers, which rose 188% to $600,022, while franchise fees fell 35% to $541,584 as franchisees declined to 21 from 39.
Operating expenses excluding prior share‑based compensation increased, notably selling and marketing (up 144% to $560,577), research and development ($138,618), and allowance for expected credit losses ($286,048, mainly on franchisee loans). Because a $19,950,000 share‑based payment recorded in 2025 did not recur, the net loss narrowed sharply to $918,282 from $19,835,994. Cash and cash equivalents decreased to $627,851 as $5,029,644 was placed in short‑term bank investments; total current assets were $6,783,004 against total liabilities of $2,073,806.
Park Ha Biological Technology Co., Ltd. reports that shareholders approved extensive capital and governance changes at an Extraordinary General Meeting and a Class A Meeting held on July 13, 2026. As of the July 2, 2026 record date, 6,364,216 shares were issued, including 5,983,216 Class A Ordinary Shares and 381,000 Class B Ordinary Shares.
Shareholders approved increasing authorised share capital from US$3,000,000 (3,000,000,000 ordinary shares) to US$300,000,000 (300,000,000,000 ordinary shares), comprising 240,000,000,000 Class A and 60,000,000,000 Class B shares of par value US$0.001 each. The Board was authorised, for three years, to carry out share consolidations with an aggregate ratio between 2-for-1 and 5,000-for-1, and share subdivisions between 2-for-1 and 100-for-1.
All resolutions at the EGM passed with over 10.28 million votes in favour versus about 22,000 against. Class A shareholders and the sole Class B holder separately approved increasing the voting rights of each Class B share from 20 votes to 100 votes. A new Amended and Restated Memorandum and Articles of Association reflecting these changes was adopted.
Park Ha Biological Technology Co., Ltd. filed a Form 6-K to report that its North American Amazon store has been officially approved and all registration procedures are complete. This means the company can begin selling its skincare products directly to consumers through Amazon’s North American marketplace.
The company describes this step as a key milestone in its global expansion strategy, saying the Amazon onboarding process involved strict standards around brand qualifications, compliance, and market reputation. It views the approval as recognition of its brand strength, product competitiveness, and operational systems.
Park Ha plans to use Amazon as its primary international platform, relying on Fulfillment by Amazon logistics and data tools to tailor products for North American consumers and increase brand visibility. The company, founded in 2016, currently operates five directly owned stores and supports 22 franchisees in China under its “Park Ha” skincare brand.
Park Ha Biological Technology Co., Ltd. is asking shareholders to approve a major increase in authorised share capital to 300,000,000,000 ordinary shares, split into 240,000,000,000 Class A and 60,000,000,000 Class B shares, each with US$0.001 par value.
The company is also seeking three-year authority for the board to execute dual-class share consolidations (reverse splits) with aggregate ratios between 2-for-1 and 5,000-for-1, and dual-class share subdivisions between 2-for-1 and 100-for-1, without further shareholder votes, subject to Nasdaq rules. Shareholders are asked to adopt amended and restated memorandum and articles that, among other changes, formalize these mechanics and meeting procedures.
Separately, Class A shareholders and the sole Class B holder are being asked to approve a variation that would increase the voting power of each Class B Ordinary Share from 20 votes to 100 votes, significantly strengthening the super-voting class while Class A shares remain at one vote each. Record-date outstanding shares were 5,930,216 Class A and 381,000 Class B as of July 2, 2026.
Park Ha Biological Technology Co., Ltd. has filed a complete membership application with the Personal Care Products Council (PCPC), a leading North American personal care trade association. The application includes corporate qualifications, raw material compliance documentation, and product safety materials, which are under review.
The company describes this step as pivotal for building a compliance framework for the North American market and supporting its planned entry into Amazon’s North America marketplace. Through PCPC’s regulatory expertise and industry network, Park Ha Biological aims to strengthen its international expansion strategy. The company, established in 2016, currently operates five directly owned stores and works with 22 franchisees in China as of October 31, 2025.
Park Ha Biological Technology Co., Ltd. is advancing its global expansion by starting cooperation with Amazon North America and preparing to enter the North American personal care market. The company is simultaneously working on store qualification registration, Amazon brand registry enrollment, a North American compliance framework, and localized product strategies, with progress described as ahead of schedule.
This move is framed as a key step in its overseas online business and a way to tap into Amazon’s roughly 310 million annual active buyers in North America. Park Ha Biological currently operates five directly owned stores and has 22 franchisees in China as of October 31, 2025, and aims to extend its Eastern-inspired, science-based skincare offerings to a broader global audience.
Park Ha Biological Technology Co., Ltd. has entered a comprehensive strategic partnership with Hong Kong–listed Cloud Factory Technology Holdings Limited to build an AI-driven ecosystem for the beauty industry. The collaboration aims to address offline beauty chains’ challenges such as uneven customer flows, repetitive back-office work and manual inventory management.
Cloud Factory contributes Internet Data Center, edge computing and large-scale AI model capabilities, while Park Ha Biological brings skincare product expertise and franchise operations experience. The partners plan a vertical smart system to enhance organizational efficiency, optimize store space use, and implement AI-powered supply chain and inventory tools. In pilot implementations, backend operational efficiency is expected to increase by up to 1.5 times, supporting a shift from expansion-led growth to data-driven, intelligent and lean operations across Park Ha’s network of directly operated stores and franchisees.
Park Ha Biological Technology Co., Ltd. completed a registered direct offering of its securities, raising gross proceeds of approximately $2.0 million. The company sold 1,133,332 Class A ordinary shares and issued pre-funded warrants to purchase up to 200,000 additional Class A ordinary shares at a combined purchase price of $1.50 per share and warrant. The pre-funded warrants are exercisable immediately at an exercise price of $0.00001 per share and remain outstanding until fully exercised. Park Ha plans to use the net proceeds for working capital and other general corporate purposes. D. Boral Capital LLC acted as the sole placement agent and received an 8% cash success fee plus certain expenses.
Park Ha Biological Technology Co., Ltd. is registering 1,133,332 Class A Ordinary Shares and pre-funded warrants exercisable for up to 200,000 Class A Ordinary Shares. The prospectus supplement states the per-share public offering price is $1.50 and each Pre-Funded Warrant is priced at $1.49999 with an exercise price of $0.00001 per share, subject to a beneficial ownership cap of 4.99% (or at the holder's prior election, 9.99%). The filing lists 4,543,884 Class A Ordinary Shares and 381,000 Class B Ordinary Shares outstanding prior to this offering and shows pro forma Class A outstanding of 5,677,216 (or 5,877,216 if Pre-Funded Warrants are exercised). The company estimates net proceeds of approximately $1.74M assuming full exercise of the Pre-Funded Warrants and states proceeds will be used for working capital and general corporate purposes.
Park Ha Biological Technology Co., Ltd. has priced a registered direct offering of up to 1,133,332 Class A ordinary shares and pre-funded warrants to purchase up to 200,000 Class A shares at a combined price of $1.50 per security. The Company expects gross proceeds of approximately $2.0 million, with closing anticipated on or about June 15, 2026, subject to customary conditions. Net proceeds are intended for general corporate and working capital purposes.
The securities are being issued under an effective Form F-3 shelf registration statement that was declared effective on June 8, 2026, and a prospectus supplement and accompanying prospectus will be filed with the SEC. D. Boral Capital LLC is acting as the sole placement agent. Park Ha Biological operates the “Park Ha” skincare brand, with five directly operated stores and 22 franchisees in China as of October 31, 2025.